Fluorouracil 50mg/ml Injection.
Sponsors
Vastra Gotalandsregionen, Amsterdam UMC, Astellas Pharma Global Development Inc., AbbVie Deutschland GmbH & Co. KG
Conditions
Adenocarcinoma of the gastroesophageal junctionAdvanced cancer of the stomach or the gastroesophageal junctionAdvanced pancreatic cancermetastatic pancreatic cancerpreviously untreated metastatic or locally advanced esophagogastric cancer
Phase 2
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination with Chemotherapy and/or Immunotherapy in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Tumors are Claudin (CLDN) 18.2 Positive.
Active, not recruitingCTIS2024-511649-21-00
Start: 2018-08-01Target: 48Updated: 2026-01-23
Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)
Active, not recruitingCTIS2023-509287-26-00
Start: 2019-07-01Target: 322Updated: 2025-11-04
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy
Active, not recruitingCTIS2023-509463-24-01
Start: 2019-11-04Target: 146Updated: 2025-01-09
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects with Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)
RecruitingCTIS2024-513008-32-00
Start: 2025-12-17Target: 50Updated: 2025-12-12